By Bruce C. Baguley (Author), David J. Kerr (Author)

ISBN-10: 0080490441

ISBN-13: 9780080490441

ISBN-10: 0120726513

ISBN-13: 9780120726516

The following in one resource is an entire spectrum of rules at the improvement of latest anticancer medicines. Containing concise reports of multidisciplinary fields of study, this publication deals a wealth of principles on present and destiny molecular goals for drug layout, together with sign transduction, the cellphone department cycle, and programmed mobilephone loss of life. particular descriptions of resources for brand spanking new medications and techniques for checking out and medical trial layout also are supplied. KEY FEATURES:* One paintings that may be consulted for all facets of anticancer drug improvement* Concise stories of analysis fields, mixed with sensible clinical element, written by way of the world over revered specialists* A wealth of rules on present and destiny molecular objectives for drug layout, together with sign transduction, the cellphone department cycle, and programmed mobile demise * particular descriptions of the resources of latest anticancer medications, together with combinatorial chemistry, phage demonstrate, and ordinary items* dialogue of ways new medicines should be validated in preclinical structures, together with the newest know-how of robot assay platforms, mobile tradition, and experimental animal suggestions* thousands of references that permit the reader to entry proper medical and scientific literature* transparent illustrations, a few in colour, that supply either realizing of the sphere and fabric for instructing

Show description

Read or Download Anticancer Drug Development PDF

Similar oncology books

Get Clinical Pain Management Cancer Pain, 2nd edition PDF

Now divided into 4 elements, the second one version of melanoma discomfort offers wide insurance of the problems that come up within the administration of malignancy-related soreness, from easy technology, via finish of lifestyles care and linked moral matters, to cures, either scientific and complementary. half One reports foundation concerns in melanoma discomfort administration, together with epidemiology, pharmacology, history-taking and sufferer overview and teamworking.

Mohammad R. S. Keshtgar BSc, MB, BS, FRCSI, FRGS(Gen), Wendy's The Sentinel Node in Surgical Oncology PDF

During this quantity an account is given of the applied sciences appropriate to the detection of sentinel lymph nodes within the context of surgical oncology. it is a quickly and evolving box, and the medical purposes mentioned during this quantity are interesting and demanding. A multidisciplinary workforce used to be assembled to debate this topic within the mild of direct adventure won by way of all the teams within the earlier yr.

Get Caring for Dying People of Different Faiths PDF

'This booklet is a tribute to professional nursing. it may be visible as a party of all that's strong in nursing. It additionally units out the trail for nursing that's focused on relationships - the essence of person-centred nursing relies at the caliber of relationships either among nurse the buyer and others and likewise among nurses their colleagues and friends.

Extra resources for Anticancer Drug Development

Example text

Liu, T. , McDonnell, T. , Rao, J. , Levin, V. , and Kyritsis, A. P. (1998). Overexpression of E2F-1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo. Nat. Med. 4, 685–690. Funk, J. , Harry, J. , and Galloway, D. A. (1997). Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. Genes Dev. 11, 2090–2100. , Lush, R. , (1998). Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein.

Norman, T. , Schow, S. , et al. (1997). CVT-313, a specific and potent inhibitor of CDK2 that prevents neointimal proliferation. J. Biol. Chem. 272, 29207–29211. Brown, A. , Lee, C. , Schwarz, J. , and Chung, J. H. (1999). A human Cds1-related kinase that functions downstream of ATM protein in the cellular response to DNA damage. Proc. Natl. Acad. Sci. USA 96, 3745–3750. Brunn, G. , Lawrence, J. , and Abraham, R. T. (1996). Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002.

1994). , 1999). , 1999) Indirubin-5-sulfonic acid 20 POMMIER, YU, AND KOHN FIGURE 4 Structure of purine inhibitors of CDKs. , 1998). , 1998). , 1999a,b). , 1994). Flavopiridol (Fig. , 1998) in cell culture. , 1996). , 1999). , 2000). Flavopiridol exhibits antitumor activity in a preclinical model (Senderowicz and Sausville, 2000) and is synergistic with existing anticancer agents (Bible and Kaufmann, 1997). Flavopiridol is presently in phase II clinical trials as 72-hour continuous infusions.

Download PDF sample

Anticancer Drug Development by Bruce C. Baguley (Author), David J. Kerr (Author)

by James

Rated 4.56 of 5 – based on 20 votes